Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
157 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cancer Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2016, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape. Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 5, 3, 19, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Cancer Pain. Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Cancer Pain Overview 8 Therapeutics Development 9 Pipeline Products for Cancer Pain - Overview 9 Pipeline Products for Cancer Pain - Comparative Analysis 10 Cancer Pain - Therapeutics under Development by Companies 11 Cancer Pain - Therapeutics under Investigation by Universities/Institutes 13 Cancer Pain - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Cancer Pain - Products under Development by Companies 18 Cancer Pain - Products under Investigation by Universities/Institutes 21 Cancer Pain - Companies Involved in Therapeutics Development 22 Alexza Pharmaceuticals Inc 22 AngioChem Inc 23 Aoxing Pharmaceutical Company Inc 24 Aphios Corp 25 AstraZeneca Plc 26 Benitec Biopharma Ltd 27 BioDelivery Sciences International Inc 28 ChironWells GmbH 29 Colby Pharmaceutical Company 30 Daiichi Sankyo Company Ltd 31 Dompe Farmaceutici SpA 32 Fujimoto Pharmaceutical Corp 33 Grunenthal GmbH 34 GW Pharmaceuticals Plc 35 Hisamitsu Pharmaceutical Co Inc 36 Immupharma Plc 37 IntelGenx Corp 38 iX Biopharma Ltd 39 Kancera AB 40 Klaria Pharma Holding AB 41 Komipharm International Co Ltd 42 KPI Therapeutics Inc 43 Neurocentrx Pharma Ltd 44 Nippon Kayaku Co Ltd 45 Orion Oyj 46 Pain Therapeutics Inc 47 Pfizer Inc 48 Pharmaleads SA 49 Recordati SpA 50 Ribomic Inc. 51 Trillium Therapeutics Inc 52 Virobay Inc 53 WEX Pharmaceuticals Inc 54 Zynerba Pharmaceuticals Inc 55 Cancer Pain - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Target 57 Assessment by Mechanism of Action 60 Assessment by Route of Administration 63 Assessment by Molecule Type 65 Drug Profiles 67 ANG-2002 - Drug Profile 67 AQU-118 - Drug Profile 68 AZD-8797 - Drug Profile 69 BBI-11008 - Drug Profile 71 buprenorphine hydrochloride - Drug Profile 72 cebranopadol - Drug Profile 73 CPC-111 - Drug Profile 76 crotalphine - Drug Profile 77 CSTI-200 - Drug Profile 78 dexmedetomidine hydrochloride - Drug Profile 79 dronabinol - Drug Profile 81 Drug 1 for Migraine and Cancer Pain - Drug Profile 82 Drug 2 for Migraine and Cancer Pain - Drug Profile 83 Drug 3 for Migraine and Cancer Pain - Drug Profile 84 Drug for Cancer Neuropathic Pain - Drug Profile 85 Drug for Migraine and Cancer Pain - Drug Profile 86 fentanyl - Drug Profile 87 fentanyl citrate - Drug Profile 88 fentanyl citrate - Drug Profile 90 fentanyl citrate - Drug Profile 91 fentanyl citrate ER - Drug Profile 92 gabapentin - Drug Profile 93 HP-3150 - Drug Profile 94 HS-198 - Drug Profile 95 hydromorphone hydrochloride - Drug Profile 96 HYLP-002 - Drug Profile 97 INT-0010 - Drug Profile 98 IPP-102199 - Drug Profile 99 methadone hydrochloride - Drug Profile 100 nabiximols - Drug Profile 101 Nervarna - Drug Profile 108 PAX-1 - Drug Profile 109 Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain - Drug Profile 110 Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile 111 PL-265 - Drug Profile 112 QX-314 - Drug Profile 113 RBM-004 - Drug Profile 114 RBM-007 - Drug Profile 115 resiniferatoxin - Drug Profile 116 saracatinib difumarate - Drug Profile 118 Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 120 Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 121 Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 122 Small Molecules for Pancreatic Cancer and Perineural Invasion - Drug Profile 123 tanezumab - Drug Profile 124 Tetrodotoxin - Drug Profile 127 tilidine hydrochloride - Drug Profile 129 U-2902 - Drug Profile 130 VBY-825 - Drug Profile 132 zucapsaicin - Drug Profile 133 ZYN-001 - Drug Profile 135 Cancer Pain - Dormant Projects 137 Cancer Pain - Discontinued Products 141 Cancer Pain - Product Development Milestones 142 Featured News & Press Releases 142 Appendix 152 Methodology 152 Coverage 152 Secondary Research 152 Primary Research 152 Expert Panel Validation 152 Contact Us 152 Disclaimer 153
List of Tables
Number of Products under Development for Cancer Pain, H2 2016 13 Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Number of Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Comparative Analysis by Late Stage Development, H2 2016 18 Comparative Analysis by Clinical Stage Development, H2 2016 19 Comparative Analysis by Early Stage Development, H2 2016 20 Comparative Analysis by Unknown Stage Development, H2 2016 21 Products under Development by Companies, H2 2016 22 Products under Development by Companies, H2 2016 (Contd..1) 23 Products under Development by Companies, H2 2016 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2016 25 Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H2 2016 26 Cancer Pain - Pipeline by AngioChem Inc, H2 2016 27 Cancer Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016 28 Cancer Pain - Pipeline by Aphios Corp, H2 2016 29 Cancer Pain - Pipeline by AstraZeneca Plc, H2 2016 30 Cancer Pain - Pipeline by Benitec Biopharma Ltd, H2 2016 31 Cancer Pain - Pipeline by BioDelivery Sciences International Inc, H2 2016 32 Cancer Pain - Pipeline by ChironWells GmbH, H2 2016 33 Cancer Pain - Pipeline by Colby Pharmaceutical Company, H2 2016 34 Cancer Pain - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 35 Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H2 2016 36 Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2016 37 Cancer Pain - Pipeline by Grunenthal GmbH, H2 2016 38 Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016 39 Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016 40 Cancer Pain - Pipeline by Immupharma Plc, H2 2016 41 Cancer Pain - Pipeline by IntelGenx Corp, H2 2016 42 Cancer Pain - Pipeline by iX Biopharma Ltd, H2 2016 43 Cancer Pain - Pipeline by Kancera AB, H2 2016 44 Cancer Pain - Pipeline by Klaria Pharma Holding AB, H2 2016 45 Cancer Pain - Pipeline by Komipharm International Co Ltd, H2 2016 46 Cancer Pain - Pipeline by KPI Therapeutics Inc, H2 2016 47 Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2016 48 Cancer Pain - Pipeline by Nippon Kayaku Co Ltd, H2 2016 49 Cancer Pain - Pipeline by Orion Oyj, H2 2016 50 Cancer Pain - Pipeline by Pain Therapeutics Inc, H2 2016 51 Cancer Pain - Pipeline by Pfizer Inc, H2 2016 52 Cancer Pain - Pipeline by Pharmaleads SA, H2 2016 53 Cancer Pain - Pipeline by Recordati SpA, H2 2016 54 Cancer Pain - Pipeline by Ribomic Inc., H2 2016 55 Cancer Pain - Pipeline by Trillium Therapeutics Inc, H2 2016 56 Cancer Pain - Pipeline by Virobay Inc, H2 2016 57 Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2016 58 Cancer Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 59 Assessment by Monotherapy Products, H2 2016 60 Number of Products by Stage and Target, H2 2016 62 Number of Products by Stage and Mechanism of Action, H2 2016 65 Number of Products by Stage and Route of Administration, H2 2016 68 Number of Products by Stage and Molecule Type, H2 2016 70 Cancer Pain - Dormant Projects, H2 2016 141 Cancer Pain - Dormant Projects (Contd..1), H2 2016 142 Cancer Pain - Dormant Projects (Contd..2), H2 2016 143 Cancer Pain - Dormant Projects (Contd..3), H2 2016 144 Cancer Pain - Discontinued Products, H2 2016 145
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
